Mirae Asset Global Etfs Holdings Ltd. Viridian Therapeutics, Inc.\De Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 48,400 shares of VRDN stock, worth $698,896. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,400
Previous 34,410
40.66%
Holding current value
$698,896
Previous $782,000
18.54%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding VRDN
# of Institutions
199Shares Held
79.2MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$68.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$66.4 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$65.3 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$56.1 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$50.9 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $576M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...